Market Access
One year after MFN: How US policy is reshaping the global ph...
Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.
News
Aicuris acquisition delivers new drug for Asahi Kasei
Asahi Kasei's $920m takeover of Germany's Aicuris in April has paid off with FDA approval for the herpes simplex virus drug at the heart of the deal.
News
Pfizer's Tukysa greenlit for earlier use in breast cancer
Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
News
PhRMA sues Trump administration over GLOBE rebate scheme
PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.
News
Rhapsido is first drug cleared for chronic hives disorder SD
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
